GSK’s supplemental Biologics License Application for its PD-1-blocking antibody therapy has been accepted for review by FDA.
The new Verafit products from STERIS are designed to help manufacturers conform to regulatory requirements laid out in Annex 1.
The health data science division of Optima Partners, bioXcelerate, has released a tool aimed at accelerating the drug discovery process.
Given the criticality of fill/finish processes, it is clear that automation is the next technological step.
AstraZeneca has completed its acquisition of Icosavax, gaining the IVX-A12 vaccine candidate that targets RSV and hMPV.
GSK is expanding its respiratory biologics portfolio with its acquisition of Aiolos Bio and its novel therapy, AIO-001.
NICE has recommended the use of AbbVie's Tepkinly as a treatment option for eligible adults with diffuse large B-cell lymphoma.
Despite slow growth over recent years, the CAR-T cell therapy space is expected to see considerable advancements in the near future.
IMU Biosciences has secured £11.5 million in its Series A financing round.
The acquisition marks a pivotal expansion for the company into the US market.